1 | 16,5% Cutaquig | - | - | - | - | 1件: 65 65 💬 |
2 | 2(S)-(ACETYLAMINO)-4-METHYLPENTANOIC ACID | - | - | - | - | 2件: 19 19, 65 💬 |
3 | 36-482-Hyaluronoglucosaminidase PH20 (rHuPH20) | 1件: Hyaluronidase Hyaluronidase | 3件: Hyaluronidase
Hyaluronidase
,
Hyaluronidase
,
Hyaluronidase
💬 | - | - | 1件: 65 65 💬 |
4 | A10BK03 | - | - | - | - | 1件: 65 65 💬 |
5 | Abatacept | 1件: Abatacept Abatacept | 1件: Abatacept
Abatacept
💬 | 2件: CD80 CD80, CD86 💬 | 13件: Allograft rejection Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Virion - Adenovirus 💬 | 26件: 11 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬 |
6 | Acetyl-l-leucine | 2件: L-Acetylleucine L-Acetylleucine, Leucine | 1件: Leucine
Leucine
💬 | - | - | 2件: 19 19, 65 💬 |
7 | Acoziborole | 1件: Acoziborole Acoziborole | - | - | - | 1件: 65 65 💬 |
8 | Acoziborole (SCYX-7158) | 1件: Acoziborole Acoziborole | - | - | - | 1件: 65 65 💬 |
9 | ADA gene transfer | - | - | - | - | 1件: 65 65 💬 |
10 | ADA PBSC | - | - | - | - | 1件: 65 65 💬 |
11 | ADA Umbilical Cord Blood Cells | - | - | - | - | 1件: 65 65 💬 |
12 | Adagen | 1件: Pegademase Pegademase | 1件: Pegademase bovine
Pegademase bovine
💬 | - | - | 1件: 65 65 💬 |
13 | Adenosine | 1件: Adenosine Adenosine | 1件: Adenosine
Adenosine
💬 | 4件: ADORA1 ADORA1, ADORA2A, ADORA2B, ADORA3 💬 | 12件: Alcoholism Alcoholism, Calcium signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 3件: 13 13, 58, 65 💬 |
14 | Administration of drug (Interferon-gamma 1-b) subcutaneously | - | - | - | - | 1件: 65 65 💬 |
15 | Adverse Reactions of Gammagard subcutaneously at Week 12 | - | - | - | - | 1件: 65 65 💬 |
16 | Adverse Reactions of Gammagard subcutaneously at Week 24 | - | - | - | - | 1件: 65 65 💬 |
17 | Adverse Reactions of Gammagard subcutaneously at Week 36 | - | - | - | - | 1件: 65 65 💬 |
18 | Adverse Reactions of Gammagard subdermally at Week 12 | - | - | - | - | 1件: 65 65 💬 |
19 | Adverse Reactions of Gammagard subdermally at Week 24 | - | - | - | - | 1件: 65 65 💬 |
20 | Adverse Reactions of Gammagard subdermally at Week 36 | - | - | - | - | 1件: 65 65 💬 |
21 | ALDESLEUKIN | 1件: Aldesleukin Aldesleukin | 1件: Aldesleukin
Aldesleukin
💬 | 3件: IL2RA IL2RA, IL2RB, IL2RG 💬 | 14件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Inflammatory bowel disease, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Primary immunodeficiency, Th1 and Th2 cell differentiation, Th17 cell differentiation, Transcriptional misregulation in cancer, Viral protein interaction with cytokine and cytokine receptor 💬 | 4件: 49 49, 65, 96, 97 💬 |
22 | Alefacept | 1件: Alefacept Alefacept | 1件: Alefacept
Alefacept
💬 | 1件: CD58 CD58 💬 | 2件: Cell adhesion molecules Cell adhesion molecules, Epstein-Barr virus infection 💬 | 6件: 37 37, 60, 65, 164, 284, 285 💬 |
23 | ALEMTUZUMAB | 1件: Alemtuzumab Alemtuzumab | 1件: Alemtuzumab
Alemtuzumab
💬 | 1件: CD52 CD52 💬 | - | 17件: 13 13, 15, 19, 20, 36, 43, 44, 46, 51, 60, 63, 65, 85, 96, 164, 283, 284 💬 |
24 | Alemtuzumab 0.2 mg | 1件: Alemtuzumab Alemtuzumab | 1件: Alemtuzumab
Alemtuzumab
💬 | 1件: CD52 CD52 💬 | - | 2件: 65 65, 164 💬 |
25 | Alemtuzumab 0.3 mg | 1件: Alemtuzumab Alemtuzumab | 1件: Alemtuzumab
Alemtuzumab
💬 | 1件: CD52 CD52 💬 | - | 2件: 65 65, 164 💬 |
26 | Allogeneic peripheral blood stem cell | - | - | - | - | 1件: 65 65 💬 |
27 | Anti-CD45 | - | - | - | - | 3件: 60 60, 65, 285 💬 |
28 | Anti-Thymocyte Globulin | - | - | - | - | 18件: 11 11, 13, 14, 36, 40, 41, 42, 45, 46, 49, 51, 60, 62, 65, 164, 283, 284, 285 💬 |
29 | Anti-thymocyte globulin (rabbit) | 1件: Rabbit Rabbit | - | - | - | 3件: 60 60, 65, 285 💬 |
30 | AProArt | - | - | - | - | 1件: 65 65 💬 |
31 | Argininhydrochlorid | - | - | - | - | 1件: 65 65 💬 |
32 | ARTEGENE drug product | - | - | - | - | 1件: 65 65 💬 |
33 | Asceniv™ | - | - | - | - | 1件: 65 65 💬 |
34 | Asparaginase | 1件: Asparaginase Escherichia coli Asparaginase Escherichia coli | - | - | - | 1件: 65 65 💬 |
35 | Autologous CD34 positive cells transduced with a lentiviral vector containing human WAS gene | - | - | - | - | 1件: 65 65 💬 |
36 | AUTOLOGOUS CD34+ CELLS TRANSDUCED EX-VIVO WITH THE PCCLCHIMGP91/VSVG LENTIVIRAL VECTOR | - | - | - | - | 1件: 65 65 💬 |
37 | Autologous CD34+ cells transduced with the Lentiviral vector containing the human Wiskott Aldrich Sy | - | - | - | - | 1件: 65 65 💬 |
38 | Autologous CD34+ cells transduced with WASP lentiviral vector | - | - | - | - | 1件: 65 65 💬 |
39 | Autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with lentiviral vector that encodes for the human Wiskott Aldrich Syndrome (WAS) cDNA sequence | - | - | - | - | 1件: 65 65 💬 |
40 | Autologous CD34+ HSCs transduced ex vivo with EFS lentiviral vector encoding for the human ADA gene | - | - | - | - | 1件: 65 65 💬 |
41 | AUTOLOGOUS CD34+CELLS TRANSDUCED WITH THE W1.6_HWASP_WPRE (VSVG) LENTIVIRAL VECTOR | - | - | - | - | 1件: 65 65 💬 |
42 | Autologous ex vivo gene therapy products based on the EFS LV encoding for the human adenosine deaminase (ADA) gene (EFS-ADA LV) | 1件: Adenosine Adenosine | 1件: Adenosine
Adenosine
💬 | 4件: ADORA1 ADORA1, ADORA2A, ADORA2B, ADORA3 💬 | 12件: Alcoholism Alcoholism, Calcium signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 65 65 💬 |
43 | AVTX-803 | - | - | - | - | 1件: 65 65 💬 |
44 | AVTX-803 (L-Fucose) | 1件: Fucose Fucose | - | - | - | 1件: 65 65 💬 |
45 | Azathioprine | 1件: Azathioprine Azathioprine | 1件: Azathioprine
Azathioprine
💬 | - | - | 21件: 6 6, 11, 13, 19, 35, 42, 43, 44, 45, 46, 49, 63, 65, 66, 85, 93, 94, 95, 96, 97, 162 💬 |
46 | B-Lymphocyte Stimulator (BLyS) | - | - | - | - | 1件: 65 65 💬 |
47 | Baclofen | 1件: Baclofen Baclofen | 1件: Baclofen
Baclofen
💬 | 2件: GABBR1 GABBR1, GABBR2 💬 | 7件: Estrogen signaling pathway Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬 | 8件: 2 2, 10, 13, 18, 65, 70, 149, 206 💬 |
48 | Bacteriophage | - | - | - | - | 1件: 65 65 💬 |
49 | Benznidazole | 1件: Benznidazole Benznidazole | 1件: Benznidazole
Benznidazole
💬 | - | - | 1件: 65 65 💬 |
50 | Betamethasone | 1件: Betamethasone Betamethasone | 1件: Betamethasone
Betamethasone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 8件: 2 2, 28, 46, 65, 83, 90, 96, 235 💬 |
51 | Betamethasone Oral Solution Period 1 and Period 2 | 1件: Betamethasone Betamethasone | 1件: Betamethasone
Betamethasone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 65 65 💬 |
52 | Betamethasone solution as intramuscular injection Period 1 and Period 2 | 1件: Betamethasone Betamethasone | 1件: Betamethasone
Betamethasone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 65 65 💬 |
53 | Biological sampling | - | - | - | - | 1件: 65 65 💬 |
54 | Bivigam | - | - | - | - | 1件: 65 65 💬 |
55 | BMS-188667 | - | - | - | - | 9件: 46 46, 49, 53, 65, 96, 97, 107, 222, 271 💬 |
56 | BPX-501 T cells | - | - | - | - | 4件: 65 65, 284, 285, 326 💬 |
57 | BT090 | - | - | - | - | 1件: 65 65 💬 |
58 | BT524 | - | - | - | - | 1件: 65 65 💬 |
59 | BT595 | - | - | - | - | 2件: 63 63, 65 💬 |
60 | BT681 | - | - | - | - | 1件: 65 65 💬 |
61 | BUSILVEX | 1件: Busulfan Busulfan | 1件: Busulfan
Busulfan
💬 | - | - | 4件: 19 19, 36, 60, 65 💬 |
62 | BUSILVEX - 6 MG/ML - CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO - 10 ML 8 FLACONCINI | 1件: Busulfan Busulfan | 1件: Busulfan
Busulfan
💬 | - | - | 2件: 19 19, 65 💬 |
63 | Busulfan | 1件: Busulfan Busulfan | 1件: Busulfan
Busulfan
💬 | - | - | 13件: 19 19, 20, 28, 36, 49, 51, 60, 65, 164, 274, 284, 285, 326 💬 |
64 | Busulfan test dose | 1件: Busulfan Busulfan | 1件: Busulfan
Busulfan
💬 | - | - | 1件: 65 65 💬 |
65 | Busulfan, Cyclophosphamide, ATG, GCSF | 2件: Busulfan Busulfan, Cyclophosphamide | 3件: Busulfan
Busulfan
,
Cyclophosphamide
,
Cyclophosphamide
💬 | - | - | 2件: 65 65, 284 💬 |
66 | Busulfan, Fludarabine and ATG | 2件: Busulfan Busulfan, Fludarabine | 2件: Busulfan
Busulfan
,
Fludarabine
💬 | 1件: RRM1 RRM1 💬 | 6件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Nucleotide metabolism, Purine metabolism, Pyrimidine metabolism 💬 | 1件: 65 65 💬 |
67 | Busulfan, Fludarabine, ATG, TLI | 2件: Busulfan Busulfan, Fludarabine | 2件: Busulfan
Busulfan
,
Fludarabine
💬 | 1件: RRM1 RRM1 💬 | 6件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Nucleotide metabolism, Purine metabolism, Pyrimidine metabolism 💬 | 2件: 65 65, 284 💬 |
68 | C1 ESTERASE INHIBITOR (HUMAN) | - | - | - | - | 1件: 65 65 💬 |
69 | C1 Esterase Inhibitor Human | - | - | - | - | 1件: 65 65 💬 |
70 | C1 inhibitor | 1件: Human C1-esterase inhibitor Human C1-esterase inhibitor | - | - | - | 1件: 65 65 💬 |
71 | C1 inhibitor concentrate | 1件: Human C1-esterase inhibitor Human C1-esterase inhibitor | - | - | - | 1件: 65 65 💬 |
72 | C1-esterase inhibitor [recombinant] (C1-INH-R) | 1件: Human C1-esterase inhibitor Human C1-esterase inhibitor | - | - | - | 1件: 65 65 💬 |
73 | C1-INH | 1件: Human C1-esterase inhibitor Human C1-esterase inhibitor | - | - | - | 1件: 65 65 💬 |
74 | Campath | 1件: Alemtuzumab Alemtuzumab | 1件: Alemtuzumab
Alemtuzumab
💬 | 1件: CD52 CD52 💬 | - | 12件: 19 19, 20, 49, 51, 60, 62, 65, 164, 234, 283, 285, 326 💬 |
75 | Campath -1H | 1件: Alemtuzumab Alemtuzumab | 1件: Alemtuzumab
Alemtuzumab
💬 | 1件: CD52 CD52 💬 | - | 1件: 65 65 💬 |
76 | Campath 1H | 1件: Alemtuzumab Alemtuzumab | 1件: Alemtuzumab
Alemtuzumab
💬 | 1件: CD52 CD52 💬 | - | 4件: 60 60, 65, 164, 285 💬 |
77 | Campath, Fludarabine, Cyclophosphamide | 2件: Cyclophosphamide Cyclophosphamide, Fludarabine | 3件: Cyclophosphamide
Cyclophosphamide
,
Cyclophosphamide
,
Fludarabine
💬 | 1件: RRM1 RRM1 💬 | 6件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Nucleotide metabolism, Purine metabolism, Pyrimidine metabolism 💬 | 2件: 65 65, 284 💬 |
78 | Catapresan | - | - | - | - | 2件: 65 65, 78 💬 |
79 | Catapresan 75, Tabletten | - | - | - | - | 1件: 65 65 💬 |
80 | CD3/CD19 neg allogeneic BMT | - | - | - | - | 1件: 65 65 💬 |
81 | CD3/CD19 negative allogeneic hematopoietic stem cells | - | - | - | - | 1件: 65 65 💬 |
82 | CD34 Stem Cell Selection Therapy | - | - | - | - | 3件: 60 60, 65, 284 💬 |
83 | CD34+ | - | - | - | - | 1件: 65 65 💬 |
84 | CD34+ cells transduced with ADA retrovir | - | - | - | - | 1件: 65 65 💬 |
85 | CD34+ HSCs transduced with the lentivirus vector, VSV-G pseudotyped CL20-4i-EF1a-h?c-OPT | - | - | - | - | 1件: 65 65 💬 |
86 | CD34+CELLS | - | - | - | - | 2件: 65 65, 285 💬 |
87 | CDZ173 | - | - | - | - | 2件: 53 53, 65 💬 |
88 | CL20-i4-EF1a-h?c-OPT | - | - | - | - | 1件: 65 65 💬 |
89 | Clonidine | 1件: Clonidine Clonidine | 1件: Clonidine
Clonidine
💬 | 3件: ADRA2A ADRA2A, ADRA2B, ADRA2C 💬 | 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬 | 4件: 6 6, 65, 70, 78 💬 |
90 | Clonidinhydrochlorid | - | - | - | - | 1件: 65 65 💬 |
91 | Collection of samples | - | - | - | - | 4件: 49 49, 65, 95, 107 💬 |
92 | Conjugated pneumococcal vaccine (Prevenar) | - | - | - | - | 1件: 65 65 💬 |
93 | COVID-19 Vaccine Moderna | 1件: Moderna COVID-19 Vaccine Moderna COVID-19 Vaccine | 1件: Elasomeran
Elasomeran
💬 | - | - | 4件: 46 46, 51, 65, 299 💬 |
94 | Cryopreserved EFS-ADA LV transduced patient CD34+ cells | - | - | - | - | 1件: 65 65 💬 |
95 | Cryopreserved G2SCID lentiviral vector transduced patient CD34+ cells | - | - | - | - | 1件: 65 65 💬 |
96 | Cultured Thymus Tissue | - | - | - | - | 1件: 65 65 💬 |
97 | Cultured Thymus Tissue for Implantation (CTTI) | - | - | - | - | 1件: 65 65 💬 |
98 | Cultured Thymus Tissue Implantation (CTTI) | - | - | - | - | 1件: 65 65 💬 |
99 | CUTAQUIG | - | - | - | - | 1件: 65 65 💬 |
100 | CUVITRU | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 1件: 65 65 💬 |
101 | Cuvitru 200 mg/ml solution for subcutaneous injection | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 1件: 65 65 💬 |
102 | Cyclophosphamide | 1件: Cyclophosphamide Cyclophosphamide | 2件: Cyclophosphamide
Cyclophosphamide
,
Cyclophosphamide
💬 | - | - | 44件: 11 11, 13, 14, 16, 19, 20, 26, 28, 35, 36, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 56, 60, 62, 65, 66, 84, 85, 93, 96, 162, 164, 172, 205, 222, 224, 256, 274, 283, 284, 285, 288, 326, 331 💬 |
103 | Cyclophosphamide (Cytoxan) | 1件: Cyclophosphamide Cyclophosphamide | 2件: Cyclophosphamide
Cyclophosphamide
,
Cyclophosphamide
💬 | - | - | 1件: 65 65 💬 |
104 | Cyclophosphamide 30 | 1件: Cyclophosphamide Cyclophosphamide | 2件: Cyclophosphamide
Cyclophosphamide
,
Cyclophosphamide
💬 | - | - | 3件: 65 65, 285, 326 💬 |
105 | Cyclophosphamide 40 | 1件: Cyclophosphamide Cyclophosphamide | 2件: Cyclophosphamide
Cyclophosphamide
,
Cyclophosphamide
💬 | - | - | 3件: 65 65, 285, 326 💬 |
106 | Cyclophosphamide Dose Level 1 | 1件: Cyclophosphamide Cyclophosphamide | 2件: Cyclophosphamide
Cyclophosphamide
,
Cyclophosphamide
💬 | - | - | 2件: 65 65, 284 💬 |
107 | Cyclophosphamide Dose Level 2 | 1件: Cyclophosphamide Cyclophosphamide | 2件: Cyclophosphamide
Cyclophosphamide
,
Cyclophosphamide
💬 | - | - | 2件: 65 65, 284 💬 |
108 | Cyclophosphamide Dose Level 3 | 1件: Cyclophosphamide Cyclophosphamide | 2件: Cyclophosphamide
Cyclophosphamide
,
Cyclophosphamide
💬 | - | - | 2件: 65 65, 284 💬 |
109 | Cyclophosphamide Dose Level 4 | 1件: Cyclophosphamide Cyclophosphamide | 2件: Cyclophosphamide
Cyclophosphamide
,
Cyclophosphamide
💬 | - | - | 2件: 65 65, 284 💬 |
110 | Cyclophosphamide post transplant | 1件: Cyclophosphamide Cyclophosphamide | 2件: Cyclophosphamide
Cyclophosphamide
,
Cyclophosphamide
💬 | - | - | 1件: 65 65 💬 |
111 | Cyclosporine | 1件: Cyclosporine Cyclosporine | 1件: Cyclosporine
Cyclosporine
💬 | 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 37件: 11 11, 19, 20, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 56, 58, 60, 61, 62, 63, 64, 65, 90, 95, 97, 107, 162, 164, 222, 226, 228, 234, 283, 284, 285, 302 💬 |
112 | Cyclosporins | - | - | - | - | 4件: 53 53, 60, 65, 222 💬 |
113 | Cytarabine | 1件: Cytarabine Cytarabine | 1件: Cytarabine
Cytarabine
💬 | - | - | 7件: 11 11, 13, 14, 25, 49, 60, 65 💬 |
114 | DACLIZUMAB | 1件: Daclizumab Daclizumab | 1件: Daclizumab
Daclizumab
💬 | 1件: IL2RA IL2RA 💬 | 11件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 8件: 13 13, 56, 60, 65, 97, 107, 283, 284 💬 |
115 | Danazol | 1件: Danazol Danazol | 1件: Danazol
Danazol
💬 | 3件: AR AR, ESR1, PGR 💬 | 12件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, Oocyte meiosis, Pathways in cancer, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Thyroid hormone signaling pathway 💬 | 5件: 60 60, 63, 64, 65, 285 💬 |
116 | Data collection | - | - | - | - | 1件: 65 65 💬 |
117 | Daunorubicin | 1件: Daunorubicin Daunorubicin | 1件: Daunorubicin
Daunorubicin
💬 | 2件: TOP2A TOP2A, TOP2B 💬 | 1件: Platinum drug resistance Platinum drug resistance 💬 | 1件: 65 65 💬 |
118 | DB289 | - | - | - | - | 1件: 65 65 💬 |
119 | Depletion in CD45RA graft donor | - | - | - | - | 1件: 65 65 💬 |
120 | Dexametasone Fosfato Sodico | - | - | - | - | 1件: 65 65 💬 |
121 | Dexamethasone | 1件: Dexamethasone Dexamethasone | 1件: Dexamethasone
Dexamethasone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 22件: 13 13, 14, 16, 28, 35, 46, 53, 63, 64, 65, 70, 81, 84, 96, 97, 162, 222, 235, 257, 283, 296, 299 💬 |
122 | Dexamethasone 21-dihydrogen phosphate | 3件: Dexamethasone Dexamethasone, Hydrogen, Phosphate ion | 1件: Dexamethasone
Dexamethasone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 65 65 💬 |
123 | DEXAMETHASONE SODIUM PHOSPHATE | 2件: Dexamethasone Dexamethasone, Phosphate ion | 1件: Dexamethasone
Dexamethasone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 3件: 65 65, 70, 96 💬 |
124 | Dexamethasone sodium phosphate (soluzione 25mg/ml) | 2件: Dexamethasone Dexamethasone, Phosphate ion | 1件: Dexamethasone
Dexamethasone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 65 65 💬 |
125 | DEXAMETHASONE SODIUM PHOSPHATE PH. EUR. | 2件: Dexamethasone Dexamethasone, Phosphate ion | 1件: Dexamethasone
Dexamethasone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 65 65 💬 |
126 | Dexamethasone, procarbazine | 2件: Dexamethasone Dexamethasone, Procarbazine | 2件: Dexamethasone
Dexamethasone
,
Procarbazine
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 65 65 💬 |
127 | Dextrose | 1件: Dextrose, unspecified form Dextrose, unspecified form | - | - | - | 4件: 60 60, 65, 70, 226 💬 |
128 | Dextrose, 5% in Water | 2件: Dextrose, unspecified form Dextrose, unspecified form, Water | 1件: Water
Water
💬 | - | - | 1件: 65 65 💬 |
129 | Dihydrogen | 1件: Hydrogen Hydrogen | - | - | - | 1件: 65 65 💬 |
130 | Donor peripheral blood stem cells. | - | - | - | - | 1件: 65 65 💬 |
131 | Doxorubicin | 1件: Doxorubicin Doxorubicin | 1件: Doxorubicin
Doxorubicin
💬 | 2件: TOP2A TOP2A, TOP2B 💬 | 1件: Platinum drug resistance Platinum drug resistance 💬 | 5件: 26 26, 28, 34, 65, 331 💬 |
132 | Doxorubicin, methotrexate, cyclophosphamide, L-asparaginase | 4件: Asparaginase Escherichia coli Asparaginase Escherichia coli, Cyclophosphamide, Doxorubicin, Methotrexate | 4件: Methotrexate
Methotrexate
,
Cyclophosphamide
,
Doxorubicin
,
Cyclophosphamide
💬 | 4件: DHFR DHFR, DHFR2, TOP2A, TOP2B 💬 | 6件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate, Platinum drug resistance 💬 | 1件: 65 65 💬 |
133 | EDS-EP dose range of ~14-22 mg DSP/infusion | - | - | - | - | 1件: 65 65 💬 |
134 | EDS-EP dose range of ~5-10 mg DSP/infusion | - | - | - | - | 1件: 65 65 💬 |
135 | EF1aS-ADA lentiviral vector gene modified autologous CD34+ cells | - | - | - | - | 1件: 65 65 💬 |
136 | EF1aS-ADA lentiviral vector transduced patient CD34+ cells | - | - | - | - | 1件: 65 65 💬 |
137 | Efficacy of Gammagard subcutaneously at Week 12 | - | - | - | - | 1件: 65 65 💬 |
138 | Efficacy of Gammagard subcutaneously at Week 24 | - | - | - | - | 1件: 65 65 💬 |
139 | Efficacy of Gammagard subcutaneously at Week 36 | - | - | - | - | 1件: 65 65 💬 |
140 | Efficacy of Gammagard subdermally at Week 12 | - | - | - | - | 1件: 65 65 💬 |
141 | Efficacy of Gammagard subdermally at Week 24 | - | - | - | - | 1件: 65 65 💬 |
142 | Efficacy of Gammagard subdermally at Week 36 | - | - | - | - | 1件: 65 65 💬 |
143 | Eflornithine | 1件: Eflornithine Eflornithine | 1件: Eflornithine
Eflornithine
💬 | 1件: ODC1 ODC1 💬 | 3件: Arginine and proline metabolism Arginine and proline metabolism, Glutathione metabolism, Metabolic pathways 💬 | 1件: 65 65 💬 |
144 | Eflornithine plus Nifurtimox combination therapy | 2件: Eflornithine Eflornithine, Nifurtimox | 2件: Nifurtimox
Nifurtimox
,
Eflornithine
💬 | 1件: ODC1 ODC1 💬 | 3件: Arginine and proline metabolism Arginine and proline metabolism, Glutathione metabolism, Metabolic pathways 💬 | 1件: 65 65 💬 |
145 | ELTROMBOPAG | 1件: Eltrombopag Eltrombopag | - | - | - | 5件: 60 60, 63, 65, 284, 285 💬 |
146 | Emapalumab | 1件: Emapalumab Emapalumab | 1件: Emapalumab
Emapalumab
💬 | 1件: IFNG IFNG 💬 | 32件: African trypanosomiasis African trypanosomiasis, Allograft rejection, Amoebiasis, Antigen processing and presentation, Chagas disease, Cytokine-cytokine receptor interaction, Fluid shear stress and atherosclerosis, Graft-versus-host disease, HIF-1 signaling pathway, Hepatitis C, Herpes simplex virus 1 infection, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Leishmaniasis, Malaria, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways in cancer, Proteasome, Rheumatoid arthritis, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 3件: 49 49, 65, 107 💬 |
147 | Emapalumab-Izsg | 1件: Emapalumab Emapalumab | 1件: Emapalumab
Emapalumab
💬 | 1件: IFNG IFNG 💬 | 32件: African trypanosomiasis African trypanosomiasis, Allograft rejection, Amoebiasis, Antigen processing and presentation, Chagas disease, Cytokine-cytokine receptor interaction, Fluid shear stress and atherosclerosis, Graft-versus-host disease, HIF-1 signaling pathway, Hepatitis C, Herpes simplex virus 1 infection, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Leishmaniasis, Malaria, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways in cancer, Proteasome, Rheumatoid arthritis, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 65 65 💬 |
148 | Empagliflozin | 1件: Empagliflozin Empagliflozin | 1件: Empagliflozin
Empagliflozin
💬 | 1件: SLC5A2 SLC5A2 💬 | - | 6件: 58 58, 65, 67, 72, 97, 257 💬 |
149 | EP2006 | - | - | - | - | 1件: 65 65 💬 |
150 | EP2006 (Filgrastim) | 1件: Filgrastim Filgrastim | 1件: Filgrastim
Filgrastim
💬 | 1件: CSF3R CSF3R 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer 💬 | 1件: 65 65 💬 |
151 | Estradiol | 1件: Estradiol Estradiol | 1件: Estradiol
Estradiol
💬 | 2件: ESR1 ESR1, ESR2 💬 | 10件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway 💬 | 7件: 13 13, 46, 49, 65, 76, 226, 299 💬 |
152 | Estradiol valerate | 2件: Estradiol Estradiol, Estradiol valerate | 2件: Estradiol
Estradiol
,
Estradiol valerate
💬 | 2件: ESR1 ESR1, ESR2 💬 | 10件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway 💬 | 1件: 65 65 💬 |
153 | Estradiolvalerat | - | - | - | - | 1件: 65 65 💬 |
154 | Etoposide | 1件: Etoposide Etoposide | 1件: Etoposide
Etoposide
💬 | 2件: TOP2A TOP2A, TOP2B 💬 | 1件: Platinum drug resistance Platinum drug resistance 💬 | 11件: 11 11, 13, 14, 26, 28, 34, 60, 65, 85, 164, 331 💬 |
155 | Etoposide, cytarabine, mercaptopurine | 3件: Cytarabine Cytarabine, Etoposide, Mercaptopurine | 4件: Etoposide
Etoposide
,
Mercaptopurine
,
Cytarabine
,
Mercaptopurine
💬 | 3件: HPRT1 HPRT1, TOP2A, TOP2B 💬 | 5件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Platinum drug resistance, Purine metabolism 💬 | 1件: 65 65 💬 |
156 | Ex vivo culture and transduction of the patient's autologous CD34+ HSC with lentivirus vector VSV-G pseudotyped CL20- 4i-EF1alpha-hgammac-OPT vector | - | - | - | - | 1件: 65 65 💬 |
157 | Ex-vivo gene-therapy | - | - | - | - | 1件: 65 65 💬 |
158 | EZN-2279 | - | - | - | - | 1件: 65 65 💬 |
159 | FACS analyses | - | - | - | - | 1件: 65 65 💬 |
160 | Fansidar (pyrimethamine and sulfadoxine) | 2件: Pyrimethamine Pyrimethamine, Sulfadoxine | 2件: Pyrimethamine
Pyrimethamine
,
Sulfadoxine
💬 | - | - | 1件: 65 65 💬 |
161 | Fexinidazole | 1件: Fexinidazole Fexinidazole | 1件: Fexinidazole
Fexinidazole
💬 | - | - | 1件: 65 65 💬 |
162 | Fibrinogen | 1件: Fibrinogen human Fibrinogen human | - | - | - | 2件: 14 14, 65 💬 |
163 | Fibrinogen (coagulation factorI) | 1件: Fibrinogen human Fibrinogen human | - | - | - | 1件: 65 65 💬 |
164 | Fibrinogen Concentrate from Human Plasma | 1件: Fibrinogen human Fibrinogen human | - | - | - | 1件: 65 65 💬 |
165 | Filgrastim | 1件: Filgrastim Filgrastim | 1件: Filgrastim
Filgrastim
💬 | 1件: CSF3R CSF3R 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer 💬 | 28件: 2 2, 6, 13, 25, 26, 28, 34, 35, 38, 40, 41, 42, 45, 46, 49, 51, 60, 62, 65, 96, 113, 164, 256, 283, 284, 285, 296, 331 💬 |
166 | Filgrastim Hexal | 1件: Filgrastim Filgrastim | 1件: Filgrastim
Filgrastim
💬 | 1件: CSF3R CSF3R 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer 💬 | 1件: 65 65 💬 |
167 | Filgrastim, Alemtuzumab | 2件: Alemtuzumab Alemtuzumab, Filgrastim | 2件: Alemtuzumab
Alemtuzumab
,
Filgrastim
💬 | 2件: CD52 CD52, CSF3R 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer 💬 | 1件: 65 65 💬 |
168 | Fisetin | 1件: Fisetin Fisetin | - | - | - | 1件: 65 65 💬 |
169 | Flebogamma 5% DIF | - | - | - | - | 1件: 65 65 💬 |
170 | Fludarabina | 1件: Fludarabine Fludarabine | 1件: Fludarabine
Fludarabine
💬 | 1件: RRM1 RRM1 💬 | 6件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Nucleotide metabolism, Purine metabolism, Pyrimidine metabolism 💬 | 2件: 19 19, 65 💬 |
171 | Fludarabina Accord | 1件: Fludarabine Fludarabine | 1件: Fludarabine
Fludarabine
💬 | 1件: RRM1 RRM1 💬 | 6件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Nucleotide metabolism, Purine metabolism, Pyrimidine metabolism 💬 | 1件: 65 65 💬 |
172 | FLUDARABINA TEVA - 25 MG/ML CONCENTRATO PER SOLUZIONE INIETTABILE O PER INFUSIONE 1 FLACONCINO DI VETRO DA 2 ML | 1件: Fludarabine Fludarabine | 1件: Fludarabine
Fludarabine
💬 | 1件: RRM1 RRM1 💬 | 6件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Nucleotide metabolism, Purine metabolism, Pyrimidine metabolism 💬 | 1件: 65 65 💬 |
173 | Fludarabine | 1件: Fludarabine Fludarabine | 1件: Fludarabine
Fludarabine
💬 | 1件: RRM1 RRM1 💬 | 6件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Nucleotide metabolism, Purine metabolism, Pyrimidine metabolism 💬 | 19件: 11 11, 13, 28, 36, 46, 49, 51, 60, 61, 62, 65, 85, 96, 164, 283, 284, 285, 286, 326 💬 |
174 | Fludarabine monophosphate | 1件: Fludarabine Fludarabine | 1件: Fludarabine
Fludarabine
💬 | 1件: RRM1 RRM1 💬 | 6件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Nucleotide metabolism, Purine metabolism, Pyrimidine metabolism 💬 | 3件: 65 65, 284, 326 💬 |
175 | Fludarabine phosphate | 2件: Fludarabine Fludarabine, Phosphate ion | 1件: Fludarabine
Fludarabine
💬 | 1件: RRM1 RRM1 💬 | 6件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Nucleotide metabolism, Purine metabolism, Pyrimidine metabolism 💬 | 12件: 28 28, 36, 49, 51, 60, 62, 65, 96, 283, 284, 285, 286 💬 |
176 | Fludarabine phosphate 30 mg | 2件: Fludarabine Fludarabine, Phosphate ion | 1件: Fludarabine
Fludarabine
💬 | 1件: RRM1 RRM1 💬 | 6件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Nucleotide metabolism, Purine metabolism, Pyrimidine metabolism 💬 | 2件: 65 65, 164 💬 |
177 | Fludarabine phosphate 40 mg | 2件: Fludarabine Fludarabine, Phosphate ion | 1件: Fludarabine
Fludarabine
💬 | 1件: RRM1 RRM1 💬 | 6件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Nucleotide metabolism, Purine metabolism, Pyrimidine metabolism 💬 | 2件: 65 65, 164 💬 |
178 | Fludarabine, Busulfan, Thymoglobulin | 3件: Antithymocyte immunoglobulin (rabbit) Antithymocyte immunoglobulin (rabbit), Busulfan, Fludarabine | 2件: Busulfan
Busulfan
,
Fludarabine
💬 | 1件: RRM1 RRM1 💬 | 6件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Nucleotide metabolism, Purine metabolism, Pyrimidine metabolism 💬 | 1件: 65 65 💬 |
179 | Fludarabine, Melphalan, Thiotepa | 3件: Fludarabine Fludarabine, Melphalan, Thiotepa | 3件: Melphalan
Melphalan
,
Thiotepa
,
Fludarabine
💬 | 1件: RRM1 RRM1 💬 | 6件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Nucleotide metabolism, Purine metabolism, Pyrimidine metabolism 💬 | 1件: 65 65 💬 |
180 | FORTECORTIN | - | - | - | - | 2件: 28 28, 65 💬 |
181 | Fortecortin Inject 40 mg Amp. | - | - | - | - | 1件: 65 65 💬 |
182 | Fucose | 1件: Fucose Fucose | - | - | - | 1件: 65 65 💬 |
183 | G-CSF | 1件: Filgrastim Filgrastim | 1件: Filgrastim
Filgrastim
💬 | 1件: CSF3R CSF3R 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer 💬 | 16件: 2 2, 6, 11, 13, 16, 22, 47, 51, 60, 62, 65, 85, 96, 284, 285, 331 💬 |
184 | G-CSF for Conditioning before HSCT. | 1件: Filgrastim Filgrastim | 1件: Filgrastim
Filgrastim
💬 | 1件: CSF3R CSF3R 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer 💬 | 1件: 65 65 💬 |
185 | G1XCG | - | - | - | - | 1件: 65 65 💬 |
186 | G1XCGD transduced CD34+ cells | - | - | - | - | 1件: 65 65 💬 |
187 | Gadolinium | 1件: Gadolinium Gadolinium | - | - | - | 4件: 13 13, 34, 46, 65 💬 |
188 | Gadolinium For abdomen | 1件: Gadolinium Gadolinium | - | - | - | 1件: 65 65 💬 |
189 | Gadolinium For lower back | 1件: Gadolinium Gadolinium | - | - | - | 1件: 65 65 💬 |
190 | GAMMAGARD LIQUID | - | - | - | - | 1件: 65 65 💬 |
191 | Gammagard S/D (Solvent/Detergent) | - | - | - | - | 1件: 65 65 💬 |
192 | Gammaglobulin | - | - | - | - | 1件: 65 65 💬 |
193 | Gammanorm | - | - | - | - | 2件: 14 14, 65 💬 |
194 | Gammanorm 165 mg/mL | - | - | - | - | 1件: 65 65 💬 |
195 | Gammaplex | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 2件: 63 63, 65 💬 |
196 | Gammaplex (5%) | - | - | - | - | 1件: 65 65 💬 |
197 | Gammaplex (Intravenous immunoglobulin) | - | - | - | - | 1件: 65 65 💬 |
198 | Gammaplex 10 | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 1件: 65 65 💬 |
199 | GAMUNEX-C | - | - | - | - | 1件: 65 65 💬 |
200 | Gcsf | - | - | - | - | 1件: 65 65 💬 |
201 | Gene sequencing | - | - | - | - | 1件: 65 65 💬 |
202 | Gene therapy | - | - | - | - | 1件: 65 65 💬 |
203 | Gene Therapy Method for CGD | - | - | - | - | 1件: 65 65 💬 |
204 | Gene transduced PBL and/or gene transduced HSC | - | - | - | - | 1件: 65 65 💬 |
205 | Gene-Transduced Autologous CD34+ Stem Cells | - | - | - | - | 1件: 65 65 💬 |
206 | Genetically modified autologous blood stem cells | - | - | - | - | 1件: 65 65 💬 |
207 | Glycolic acid | 1件: Glycolic acid Glycolic acid | - | - | - | 1件: 65 65 💬 |
208 | Glycosade | - | - | - | - | 3件: 65 65, 256, 257 💬 |
209 | Gold | 1件: Gold Gold | - | - | - | 43件: 2 2, 5, 6, 13, 17, 34, 35, 46, 49, 50, 53, 58, 63, 65, 68, 76, 84, 86, 91, 93, 95, 96, 97, 98, 113, 137, 158, 162, 167, 171, 193, 218, 222, 224, 226, 227, 230, 271, 291, 296, 298, 310, 318 💬 |
210 | Gp91 Grans | - | - | - | - | 1件: 65 65 💬 |
211 | Granulocyte Colony Stimulating Factor | 1件: Filgrastim Filgrastim | 1件: Filgrastim
Filgrastim
💬 | 1件: CSF3R CSF3R 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer 💬 | 6件: 2 2, 28, 36, 57, 65, 85 💬 |
212 | Granulocyte colony stimulating factor (G-CSF) | 1件: Filgrastim Filgrastim | 1件: Filgrastim
Filgrastim
💬 | 1件: CSF3R CSF3R 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer 💬 | 1件: 65 65 💬 |
213 | GTG003.08 | - | - | - | - | 1件: 65 65 💬 |
214 | GTX-102 | 1件: GTX-102 GTX-102 | - | - | - | 2件: 65 65, 201 💬 |
215 | GTX-102 high dose fast Period 1 and Period 2 | 1件: GTX-102 GTX-102 | - | - | - | 1件: 65 65 💬 |
216 | GTX-102 low dose fast Period 1 and Period 2 | 1件: GTX-102 GTX-102 | - | - | - | 1件: 65 65 💬 |
217 | GTX-102 medium dose fast Period 1 and Period 2 | 1件: GTX-102 GTX-102 | - | - | - | 1件: 65 65 💬 |
218 | GTX-102 medium dose slow Period 1 and Period 2 | 1件: GTX-102 GTX-102 | - | - | - | 1件: 65 65 💬 |
219 | GVHD Prophylaxis | - | - | - | - | 2件: 60 60, 65 💬 |
220 | Haemocomplettan P | - | - | - | - | 1件: 65 65 💬 |
221 | Haemocomplettan(R) P | - | - | - | - | 1件: 65 65 💬 |
222 | Haemocomplettan(R) P 1g/2g | - | - | - | - | 1件: 65 65 💬 |
223 | Haplo BM with T cell depletion | - | - | - | - | 1件: 65 65 💬 |
224 | Haploidentical Hematopoietic Cell Transplantation | - | - | - | - | 2件: 60 60, 65 💬 |
225 | Hematopoetic Stem Cell Transplantation | - | - | - | - | 5件: 19 19, 65, 120, 160, 326 💬 |
226 | Hematopoietic Stem Cell Transplant | - | - | - | - | 1件: 65 65 💬 |
227 | Hizentra | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 4件: 14 14, 50, 51, 65 💬 |
228 | Hizentra® | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 2件: 14 14, 65 💬 |
229 | HTLP | - | - | - | - | 1件: 65 65 💬 |
230 | HUMAN FIBRINOGEN | 1件: Fibrinogen human Fibrinogen human | - | - | - | 1件: 65 65 💬 |
231 | Human Fibrinogen Concentrate | 1件: Fibrinogen human Fibrinogen human | - | - | - | 1件: 65 65 💬 |
232 | Human Immunglobulin G (IgG) | - | - | - | - | 1件: 65 65 💬 |
233 | Human Immunoglobulin | - | - | - | - | 2件: 63 63, 65 💬 |
234 | HUMAN IMMUNOGLOBULIN G | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 4件: 14 14, 50, 63, 65 💬 |
235 | Human normal immunoglobulin | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 9件: 11 11, 13, 14, 43, 45, 50, 51, 63, 65 💬 |
236 | HUMAN NORMAL IMMUNOGLOBULIN (IV) | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 4件: 11 11, 14, 63, 65 💬 |
237 | Human normal immunoglobulin (IVIg) | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 3件: 14 14, 50, 65 💬 |
238 | Human Normal Immunoglobulin (Subcutaneous - Intramuscular Immunoglobulin) | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 1件: 65 65 💬 |
239 | Human normal immunoglobulin (subcutaneous) | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 1件: 65 65 💬 |
240 | HUMAN NORMAL IMMUNOGLOBULIN FOR | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 1件: 65 65 💬 |
241 | Human normal immunoglobulin for intravenous administration | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 3件: 14 14, 51, 65 💬 |
242 | HUMAN NORMAL IMMUNOGLOBULIN FOR INTRAVENOUS USE | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 2件: 63 63, 65 💬 |
243 | Human normal immunoglobulin for intravenous use (IVIG) | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 1件: 65 65 💬 |
244 | Human normal immunoglobulin for subcutaneous administration | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 2件: 51 51, 65 💬 |
245 | Human Normal Immunoglobulin for Subcutaneous Administration (IGSC) | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 1件: 65 65 💬 |
246 | Human normal immunoglobulin G (IgG > 98% purity) | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 3件: 14 14, 63, 65 💬 |
247 | Human T Lymphoid Progenitor (HTLP) injection | - | - | - | - | 1件: 65 65 💬 |
248 | Hyaluronidase | 2件: Hyaluronidase Hyaluronidase, Hyaluronidase (human recombinant) | 3件: Hyaluronidase
Hyaluronidase
,
Hyaluronidase
,
Hyaluronidase
💬 | - | - | 5件: 14 14, 28, 51, 65, 331 💬 |
249 | Hyaluronoglucosaminidase | 1件: Hyaluronidase Hyaluronidase | 3件: Hyaluronidase
Hyaluronidase
,
Hyaluronidase
,
Hyaluronidase
💬 | - | - | 1件: 65 65 💬 |
250 | Hydroxyurea | 1件: Hydroxyurea Hydroxyurea | 1件: Hydroxyurea
Hydroxyurea
💬 | 1件: RRM2 RRM2 💬 | 7件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Nucleotide metabolism, Purine metabolism, Pyrimidine metabolism, p53 signaling pathway 💬 | 8件: 3 3, 13, 19, 20, 65, 85, 86, 284 💬 |
251 | HyQvia | 2件: Human immunoglobulin G Human immunoglobulin G, Hyaluronidase (human recombinant) | - | - | - | 2件: 14 14, 65 💬 |
252 | HyQvia 100 mg/ml solution for infusion for subcutaneous use | 2件: Human immunoglobulin G Human immunoglobulin G, Hyaluronidase (human recombinant) | - | - | - | 1件: 65 65 💬 |
253 | I10E | - | - | - | - | 3件: 14 14, 63, 65 💬 |
254 | IB 1001 | - | - | - | - | 1件: 65 65 💬 |
255 | IB1001 | - | - | - | - | 2件: 19 19, 65 💬 |
256 | Ibuprofen | 1件: Ibuprofen Ibuprofen | 1件: Ibuprofen
Ibuprofen
💬 | 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 7件: 13 13, 46, 65, 107, 113, 271, 299 💬 |
257 | IFN-gamma | - | - | - | - | 1件: 65 65 💬 |
258 | Ig VENA 50 g/l solution for infusion 100 ml vial + infusion set | - | - | - | - | 2件: 63 63, 65 💬 |
259 | IgG Next Generation | - | - | - | - | 2件: 63 63, 65 💬 |
260 | IgG Next Generation (BT595) | - | - | - | - | 1件: 65 65 💬 |
261 | IgHy10 | - | - | - | - | 1件: 65 65 💬 |
262 | IGIV, 10% | - | - | - | - | 2件: 14 14, 65 💬 |
263 | IGIV-C 10% | - | - | - | - | 1件: 65 65 💬 |
264 | IgNextGen 16% | - | - | - | - | 1件: 65 65 💬 |
265 | IGNG | - | - | - | - | 1件: 65 65 💬 |
266 | IgPro10 | - | - | - | - | 3件: 14 14, 51, 65 💬 |
267 | IgPro20 | - | - | - | - | 4件: 14 14, 50, 51, 65 💬 |
268 | IGSC 20% | - | - | - | - | 1件: 65 65 💬 |
269 | IGSC 20% 150 mg/kg | - | - | - | - | 1件: 65 65 💬 |
270 | IGSC 20% daily push versus 2 times per week pump | - | - | - | - | 1件: 65 65 💬 |
271 | IGSC 20% daily push versus every 2 weeks pump | - | - | - | - | 1件: 65 65 💬 |
272 | IGSC 20% daily push versus once a week pump | - | - | - | - | 1件: 65 65 💬 |
273 | IGSC 20% infusion | - | - | - | - | 1件: 65 65 💬 |
274 | IGSC, 16% | - | - | - | - | 1件: 65 65 💬 |
275 | IGSC, 20% | - | - | - | - | 1件: 65 65 💬 |
276 | Immune Globulin Infusion (Human), 10% | - | - | - | - | 1件: 65 65 💬 |
277 | Immune Globulin Intravenous | - | - | - | - | 1件: 65 65 💬 |
278 | Immune Globulin Intravenous (Human) | - | - | - | - | 1件: 65 65 💬 |
279 | Immune Globulin Intravenous (Human) 5% Liquid, IVIG-SN™ | - | - | - | - | 1件: 65 65 💬 |
280 | Immune Globulin Intravenous (human), 10% | - | - | - | - | 2件: 14 14, 65 💬 |
281 | Immune Globulin Intravenous (Human), 10% Solution | - | - | - | - | 1件: 65 65 💬 |
282 | Immune Globulin Intravenous (Human), 10% TVR (Triple Virally Reduced) Solution | - | - | - | - | 1件: 65 65 💬 |
283 | Immune Globulin Intravenous (IGIV) | - | - | - | - | 1件: 65 65 💬 |
284 | Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified | - | - | - | - | 1件: 65 65 💬 |
285 | Immune Globulin Subcutaneos, 20% | - | - | - | - | 1件: 65 65 💬 |
286 | Immune Globulin Subcutaneous (Human) | - | - | - | - | 2件: 14 14, 65 💬 |
287 | Immune Globulin Subcutaneous (Human) (SCIG) | - | - | - | - | 1件: 65 65 💬 |
288 | Immune Globulin Subcutaneous (Human), 20% | - | - | - | - | 1件: 65 65 💬 |
289 | Immune Globulin Subcutaneous (Human), 20% Caprylate/Chromatography Purified (IGSC 20%) | - | - | - | - | 1件: 65 65 💬 |
290 | Immune Globulin Subcutaneous (Human), 20% Solution | - | - | - | - | 1件: 65 65 💬 |
291 | Immune Globulin Subcutaneous (Human), 20%, Caprylate/Chromatography Purified | - | - | - | - | 1件: 65 65 💬 |
292 | Immune Globulin Subcutaneous, 20% | - | - | - | - | 1件: 65 65 💬 |
293 | Immune Globulin Subcutaneous, 20% Solution (IGSC, 20%) | - | - | - | - | 1件: 65 65 💬 |
294 | Immunglobulin (human) | - | - | - | - | 1件: 65 65 💬 |
295 | IMMUNOGLOBULIN G | - | - | - | - | 8件: 2 2, 11, 13, 14, 49, 50, 63, 65 💬 |
296 | Immunoglobulin G (Ig NextGen 16%) | - | - | - | - | 1件: 65 65 💬 |
297 | Immunoglobulin intravenous (human) | - | - | - | - | 1件: 65 65 💬 |
298 | IMMUNOGLOBULINA UMANA NORMALE | - | - | - | - | 2件: 51 51, 65 💬 |
299 | Immunoglobulins Intravenous (Human) | - | - | - | - | 1件: 65 65 💬 |
300 | Immunoglobulins, normal human | - | - | - | - | 1件: 65 65 💬 |
301 | Immunological diagnosis tests | - | - | - | - | 1件: 65 65 💬 |
302 | Immunosuppression Only Conditioning | - | - | - | - | 1件: 65 65 💬 |
303 | Immunosuppression Only Conditioning -Closed with amendment L | - | - | - | - | 1件: 65 65 💬 |
304 | Increlex | 1件: Mecasermin Mecasermin | 1件: Mecasermin
Mecasermin
💬 | 2件: GHR GHR, IGF1R 💬 | 33件: AMPK signaling pathway AMPK signaling pathway, Adherens junction, Autophagy - animal, Breast cancer, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endocytosis, Focal adhesion, FoxO signaling pathway, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, JAK-STAT signaling pathway, Long-term depression, Longevity regulating pathway, Longevity regulating pathway - multiple species, MAPK signaling pathway, Melanoma, Neuroactive ligand-receptor interaction, Oocyte meiosis, Ovarian steroidogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Progesterone-mediated oocyte maturation, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Signaling pathways regulating pluripotency of stem cells, Transcriptional misregulation in cancer, mTOR signaling pathway 💬 | 4件: 65 65, 78, 96, 299 💬 |
305 | Infliximab | 1件: Infliximab Infliximab | 1件: Infliximab
Infliximab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 26件: 35 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬 |
306 | Infusion of autologous cryopreserved EFS-ADA LV CD34+ cells (OTL-101) | - | - | - | - | 1件: 65 65 💬 |
307 | Infusion of autologous EFS-ADA LV CD34+ cells | - | - | - | - | 1件: 65 65 💬 |
308 | Infusion of lentiviral TYF-CGD-modified autologous stem cells | - | - | - | - | 1件: 65 65 💬 |
309 | INH | - | - | - | - | 1件: 65 65 💬 |
310 | Interferon Gamma | 1件: Interferon Gamma Interferon Gamma | - | - | - | 8件: 18 18, 65, 85, 107, 228, 299, 301, 326 💬 |
311 | INTERFERON GAMMA-1B | 2件: Interferon Gamma Interferon Gamma, Interferon gamma-1b | 1件: Interferon gamma-1b
Interferon gamma-1b
💬 | 2件: IFNGR1 IFNGR1, IFNGR2 💬 | 18件: Chagas disease Chagas disease, Cytokine-cytokine receptor interaction, HIF-1 signaling pathway, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis 💬 | 7件: 18 18, 65, 85, 228, 299, 301, 326 💬 |
312 | Interferon-gamma | - | - | - | - | 1件: 65 65 💬 |
313 | INTERLEUKIN-2 | 1件: Human interleukin-2 Human interleukin-2 | - | - | - | 10件: 2 2, 35, 49, 50, 53, 55, 65, 96, 97, 162 💬 |
314 | Intratect | - | - | - | - | 4件: 13 13, 14, 35, 65 💬 |
315 | Intravenous immunoglobulin infusion | - | - | - | - | 1件: 65 65 💬 |
316 | Intravenous infusion of transduced cells | - | - | - | - | 1件: 65 65 💬 |
317 | Itraconazole | 1件: Itraconazole Itraconazole | 1件: Itraconazole
Itraconazole
💬 | - | - | 6件: 3 3, 46, 65, 96, 227, 299 💬 |
318 | IV treatment with IGSC, 10% | - | - | - | - | 1件: 65 65 💬 |
319 | IVIG | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 7件: 11 11, 13, 14, 17, 50, 51, 65 💬 |
320 | IVIG-PEG | - | - | - | - | 1件: 65 65 💬 |
321 | Jardiance | 1件: Empagliflozin Empagliflozin | 1件: Empagliflozin
Empagliflozin
💬 | 1件: SLC5A2 SLC5A2 💬 | - | 1件: 65 65 💬 |
322 | JSP191 | - | - | - | - | 2件: 65 65, 285 💬 |
323 | Kedrion IVIG 10% | - | - | - | - | 1件: 65 65 💬 |
324 | KIg10 | - | - | - | - | 1件: 65 65 💬 |
325 | Kineret | 1件: Anakinra Anakinra | 1件: Anakinra
Anakinra
💬 | 2件: IL1R1 IL1R1, IL1R2 💬 | 15件: Amoebiasis Amoebiasis, Cytokine-cytokine receptor interaction, Fluid shear stress and atherosclerosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Inflammatory mediator regulation of TRP channels, MAPK signaling pathway, NF-kappa B signaling pathway, Osteoclast differentiation, Pathogenic Escherichia coli infection, Prostate cancer, Shigellosis, Th17 cell differentiation, Transcriptional misregulation in cancer 💬 | 9件: 28 28, 41, 46, 49, 65, 106, 107, 266, 299 💬 |
326 | KIOVIG | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 2件: 14 14, 65 💬 |
327 | KIOVIG 100 mg/ml solution for infusion | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 2件: 14 14, 65 💬 |
328 | KLH | - | - | - | - | 2件: 13 13, 65 💬 |
329 | KVD824 | - | - | - | - | 1件: 65 65 💬 |
330 | KVD824 300 mg Compresse a rilascio modificato | - | - | - | - | 1件: 65 65 💬 |
331 | KVD824 300 mg Modified Release Tablets | 1件: Manganese citrate Manganese citrate | - | - | - | 1件: 65 65 💬 |
332 | KVD824 hydrochloride | - | - | - | - | 1件: 65 65 💬 |
333 | KVD900 | - | - | - | - | 1件: 65 65 💬 |
334 | KVD900 100 mg Film Coated Tablet | - | - | - | - | 1件: 65 65 💬 |
335 | KVD900 300 mg | - | - | - | - | 1件: 65 65 💬 |
336 | KVD900 300 mg Film Coated Tablet | - | - | - | - | 1件: 65 65 💬 |
337 | KVD900 600 mg | - | - | - | - | 1件: 65 65 💬 |
338 | L-Arginin | 1件: Arginine Arginine | 1件: Arginine
Arginine
💬 | - | - | 1件: 65 65 💬 |
339 | L-Arginin-hydrochlorid-einmolar Fresenius | 1件: Arginine Arginine | 1件: Arginine
Arginine
💬 | - | - | 1件: 65 65 💬 |
340 | L-asparaginase | 1件: Asparaginase Escherichia coli Asparaginase Escherichia coli | - | - | - | 1件: 65 65 💬 |
341 | L-fucose | 1件: Fucose Fucose | - | - | - | 1件: 65 65 💬 |
342 | LADICell | - | - | - | - | 1件: 65 65 💬 |
343 | Lapine T-Lymphocyte Immune Globulin | 1件: Antithymocyte immunoglobulin (rabbit) Antithymocyte immunoglobulin (rabbit) | - | - | - | 4件: 62 62, 65, 283, 286 💬 |
344 | Lemtrada | 1件: Alemtuzumab Alemtuzumab | 1件: Alemtuzumab
Alemtuzumab
💬 | 1件: CD52 CD52 💬 | - | 2件: 13 13, 65 💬 |
345 | Leniolisib | 1件: Leniolisib Leniolisib | 1件: Leniolisib
Leniolisib
💬 | 3件: PIK3CA PIK3CA, PIK3CB, PIK3CD 💬 | 106件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, AMPK signaling pathway, Acute myeloid leukemia, Aldosterone-regulated sodium reabsorption, Alzheimer disease, Amoebiasis, Apoptosis, Autophagy - animal, Axon guidance, B cell receptor signaling pathway, Bacterial invasion of epithelial cells, Breast cancer, C-type lectin receptor signaling pathway, Carbohydrate digestion and absorption, Cellular senescence, Central carbon metabolism in cancer, Chagas disease, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Choline metabolism in cancer, Cholinergic synapse, Chronic myeloid leukemia, Colorectal cancer, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, Epstein-Barr virus infection, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, FoxO signaling pathway, Gastric cancer, Glioma, GnRH secretion, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory mediator regulation of TRP channels, Influenza A, Inositol phosphate metabolism, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leukocyte transendothelial migration, Lipid and atherosclerosis, Longevity regulating pathway, Longevity regulating pathway - multiple species, Measles, Melanoma, Metabolic pathways, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-alcoholic fatty liver disease, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Phosphatidylinositol signaling system, Phospholipase D signaling pathway, Platelet activation, Platinum drug resistance, Prion disease, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Shigellosis, Signaling pathways regulating pluripotency of stem cells, Small cell lung cancer, Sphingolipid signaling pathway, Spinocerebellar ataxia, T cell receptor signaling pathway, TNF signaling pathway, Thyroid hormone signaling pathway, Toll-like receptor signaling pathway, Type II diabetes mellitus, VEGF signaling pathway, Viral carcinogenesis, Yersinia infection, cAMP signaling pathway, mTOR signaling pathway 💬 | 2件: 53 53, 65 💬 |
346 | Lenograstim | 1件: Lenograstim Lenograstim | 1件: Lenograstim
Lenograstim
💬 | 1件: CSF3R CSF3R 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer 💬 | 7件: 2 2, 13, 16, 18, 19, 57, 65 💬 |
347 | Lentiviral Gene Transfer | - | - | - | - | 1件: 65 65 💬 |
348 | Lentiviral vector transduced CD34+ cells | - | - | - | - | 1件: 65 65 💬 |
349 | Leucine | 1件: Leucine Leucine | 1件: Leucine
Leucine
💬 | - | - | 6件: 6 6, 19, 65, 283, 284, 299 💬 |
350 | LFB-IgSC | - | - | - | - | 1件: 65 65 💬 |
351 | MabThera | 1件: Rituximab Rituximab | 1件: Rituximab
Rituximab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 22件: 11 11, 13, 14, 19, 35, 43, 44, 46, 49, 50, 51, 52, 53, 61, 63, 64, 65, 83, 93, 162, 222, 271 💬 |
352 | MABTHERA - 2 FIALE 100 MG 10 ML | 1件: Rituximab Rituximab | 1件: Rituximab
Rituximab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 2件: 19 19, 65 💬 |
353 | Mavorixafor | - | - | - | - | 1件: 65 65 💬 |
354 | MBM-01 | - | - | - | - | 1件: 65 65 💬 |
355 | MCTLs | - | - | - | - | 1件: 65 65 💬 |
356 | Melarsoprol | 1件: Melarsoprol Melarsoprol | 1件: Melarsoprol
Melarsoprol
💬 | - | - | 1件: 65 65 💬 |
357 | Melarsoprol 1.8 mg/kg/d, 10d + eflornithine 400 mg/kg/d, 7d | 2件: Eflornithine Eflornithine, Melarsoprol | 2件: Melarsoprol
Melarsoprol
,
Eflornithine
💬 | 1件: ODC1 ODC1 💬 | 3件: Arginine and proline metabolism Arginine and proline metabolism, Glutathione metabolism, Metabolic pathways 💬 | 1件: 65 65 💬 |
358 | Melarsoprol 1.8 mg/kg/d, 10d + nifurtimox 15/20 mg/kg/d, 10d | 2件: Melarsoprol Melarsoprol, Nifurtimox | 2件: Melarsoprol
Melarsoprol
,
Nifurtimox
💬 | - | - | 1件: 65 65 💬 |
359 | Melphalan | 1件: Melphalan Melphalan | 1件: Melphalan
Melphalan
💬 | - | - | 15件: 11 11, 13, 14, 19, 20, 28, 60, 62, 65, 96, 164, 234, 284, 285, 299 💬 |
360 | Mercaptopurine | 1件: Mercaptopurine Mercaptopurine | 2件: Mercaptopurine
Mercaptopurine
,
Mercaptopurine
💬 | 1件: HPRT1 HPRT1 💬 | 4件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬 | 4件: 65 65, 96, 97, 164 💬 |
361 | Mesna | 1件: Coenzyme M Coenzyme M | - | - | - | 10件: 11 11, 13, 44, 45, 51, 60, 65, 85, 96, 164 💬 |
362 | Metformin | 1件: Metformin Metformin | 1件: Metformin
Metformin
💬 | 2件: PRKAA1 PRKAA1, PRKAA2 💬 | 20件: AMPK signaling pathway AMPK signaling pathway, Adipocytokine signaling pathway, Alcoholic liver disease, Apelin signaling pathway, Autophagy - animal, Circadian rhythm, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Glucagon signaling pathway, Hypertrophic cardiomyopathy, Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Non-alcoholic fatty liver disease, Oxytocin signaling pathway, PI3K-Akt signaling pathway, Thermogenesis, Tight junction, mTOR signaling pathway 💬 | 25件: 2 2, 6, 8, 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 218, 225, 233, 265, 285, 299, 301 💬 |
363 | Methotrexate | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 38件: 11 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331 💬 |
364 | Methylprednisolone | 1件: Methylprednisolone Methylprednisolone | 1件: Methylprednisolone
Methylprednisolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 46件: 2 2, 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 85, 86, 93, 95, 96, 97, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296 💬 |
365 | Methylprednisolone or Prednisolone | 2件: Methylprednisolone Methylprednisolone, Prednisolone | 2件: Methylprednisolone
Methylprednisolone
,
Prednisolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 65 65 💬 |
366 | MMF | - | - | - | - | 16件: 13 13, 35, 40, 46, 49, 50, 51, 60, 65, 66, 107, 162, 222, 224, 226, 299 💬 |
367 | Mozobil | 1件: Plerixafor Plerixafor | 1件: Plerixafor
Plerixafor
💬 | 1件: CXCR4 CXCR4 💬 | 14件: Axon guidance Axon guidance, Calcium signaling pathway, Chemokine signaling pathway, Cytokine-cytokine receptor interaction, Endocytosis, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Intestinal immune network for IgA production, Leukocyte transendothelial migration, Pathways in cancer, Regulation of actin cytoskeleton, Viral life cycle - HIV-1, Viral protein interaction with cytokine and cytokine receptor, Virion - Human immunodeficiency virus 💬 | 3件: 19 19, 65, 285 💬 |
368 | MOZOBIL - 20 MG/ML - SOLUZIONE INIETTABILE - USO SOTTOCUTANEO - FLACONCINO (VETRO) - 24 MG/1.2 ML 1 FLACONCINO | 1件: Plerixafor Plerixafor | 1件: Plerixafor
Plerixafor
💬 | 1件: CXCR4 CXCR4 💬 | 14件: Axon guidance Axon guidance, Calcium signaling pathway, Chemokine signaling pathway, Cytokine-cytokine receptor interaction, Endocytosis, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Intestinal immune network for IgA production, Leukocyte transendothelial migration, Pathways in cancer, Regulation of actin cytoskeleton, Viral life cycle - HIV-1, Viral protein interaction with cytokine and cytokine receptor, Virion - Human immunodeficiency virus 💬 | 1件: 65 65 💬 |
369 | Mozobil 20mg/mL vial (injectable solution for subcutaneous use) | 1件: Plerixafor Plerixafor | 1件: Plerixafor
Plerixafor
💬 | 1件: CXCR4 CXCR4 💬 | 14件: Axon guidance Axon guidance, Calcium signaling pathway, Chemokine signaling pathway, Cytokine-cytokine receptor interaction, Endocytosis, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Intestinal immune network for IgA production, Leukocyte transendothelial migration, Pathways in cancer, Regulation of actin cytoskeleton, Viral life cycle - HIV-1, Viral protein interaction with cytokine and cytokine receptor, Virion - Human immunodeficiency virus 💬 | 1件: 65 65 💬 |
370 | Mozobil 20mg/mL vial (injectable solution, subcutaneous use) | 1件: Plerixafor Plerixafor | 1件: Plerixafor
Plerixafor
💬 | 1件: CXCR4 CXCR4 💬 | 14件: Axon guidance Axon guidance, Calcium signaling pathway, Chemokine signaling pathway, Cytokine-cytokine receptor interaction, Endocytosis, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Intestinal immune network for IgA production, Leukocyte transendothelial migration, Pathways in cancer, Regulation of actin cytoskeleton, Viral life cycle - HIV-1, Viral protein interaction with cytokine and cytokine receptor, Virion - Human immunodeficiency virus 💬 | 1件: 65 65 💬 |
371 | Mozobil, | 1件: Plerixafor Plerixafor | 1件: Plerixafor
Plerixafor
💬 | 1件: CXCR4 CXCR4 💬 | 14件: Axon guidance Axon guidance, Calcium signaling pathway, Chemokine signaling pathway, Cytokine-cytokine receptor interaction, Endocytosis, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Intestinal immune network for IgA production, Leukocyte transendothelial migration, Pathways in cancer, Regulation of actin cytoskeleton, Viral life cycle - HIV-1, Viral protein interaction with cytokine and cytokine receptor, Virion - Human immunodeficiency virus 💬 | 1件: 65 65 💬 |
372 | Mycophenolate | 1件: Mycophenolic acid Mycophenolic acid | 1件: Mycophenolic acid
Mycophenolic acid
💬 | 2件: IMPDH1 IMPDH1, IMPDH2 💬 | 4件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬 | 36件: 2 2, 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 84, 85, 93, 95, 96, 162, 164, 222, 224, 226, 228, 234, 283, 284, 285, 300 💬 |
373 | Mycophenolate mofetil | 2件: Mycophenolate mofetil Mycophenolate mofetil, Mycophenolic acid | 2件: Mycophenolate mofetil
Mycophenolate mofetil
,
Mycophenolic acid
💬 | 2件: IMPDH1 IMPDH1, IMPDH2 💬 | 4件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬 | 34件: 2 2, 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 85, 93, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300 💬 |
374 | Mycophenolate mofetil (MMF) | 2件: Mycophenolate mofetil Mycophenolate mofetil, Mycophenolic acid | 2件: Mycophenolate mofetil
Mycophenolate mofetil
,
Mycophenolic acid
💬 | 2件: IMPDH1 IMPDH1, IMPDH2 💬 | 4件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬 | 7件: 13 13, 49, 51, 60, 65, 66, 222 💬 |
375 | Myeloablative Conditioning-Closed with amendment L | - | - | - | - | 1件: 65 65 💬 |
376 | Myeloablative Preparative Regimen | - | - | - | - | 3件: 62 62, 65, 284 💬 |
377 | MYELOSTIM | - | - | - | - | 1件: 65 65 💬 |
378 | MYELOSTIM - 34 1 FLACONCINO LIOFILIZZATO 33.6 MIU + SIRINGA PRERIEMPITA SOLVENTE 1 ML | - | - | - | - | 2件: 19 19, 65 💬 |
379 | MYELOSTIM 34 milions UI/ml - powder and solvent for solution for injection/infusion | - | - | - | - | 1件: 65 65 💬 |
380 | MYELOSTIM 34 milions UI/ml, powder and solvent for solution for injection or infusion | - | - | - | - | 1件: 65 65 💬 |
381 | N-Acetyl-L-Leucine | 2件: L-Acetylleucine L-Acetylleucine, Leucine | 1件: Leucine
Leucine
💬 | - | - | 2件: 19 19, 65 💬 |
382 | Nanogam 100 mg/ml | - | - | - | - | 1件: 65 65 💬 |
383 | Nanogam® 50 mg/ml | - | - | - | - | 1件: 65 65 💬 |
384 | NDV-3A | - | - | - | - | 1件: 65 65 💬 |
385 | NewGam | - | - | - | - | 3件: 14 14, 63, 65 💬 |
386 | Newnorm | - | - | - | - | 1件: 65 65 💬 |
387 | Nifurtimox | 1件: Nifurtimox Nifurtimox | 1件: Nifurtimox
Nifurtimox
💬 | - | - | 1件: 65 65 💬 |
388 | Nifurtimox 15/20 mg/kg/d 10d + eflornithine 400 mg/kg/d 7d | 2件: Eflornithine Eflornithine, Nifurtimox | 2件: Nifurtimox
Nifurtimox
,
Eflornithine
💬 | 1件: ODC1 ODC1 💬 | 3件: Arginine and proline metabolism Arginine and proline metabolism, Glutathione metabolism, Metabolic pathways 💬 | 1件: 65 65 💬 |
389 | Nifurtimox-Eflronithine Combination Treatment (NECT) | 1件: Nifurtimox Nifurtimox | 1件: Nifurtimox
Nifurtimox
💬 | - | - | 1件: 65 65 💬 |
390 | None | 1件: Interleukin-1 alpha, human recombinant Interleukin-1 alpha, human recombinant | - | - | - | 20件: 6 6, 46, 51, 65, 66, 78, 84, 85, 96, 97, 140, 160, 161, 171, 222, 231, 246, 271, 299, 337 💬 |
391 | Normal human immunoglobulin G | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 1件: 65 65 💬 |
392 | Norovirus -specific T-cell (NST) therapy | - | - | - | - | 1件: 65 65 💬 |
393 | Noxafil | 1件: Posaconazole Posaconazole | 1件: Posaconazole
Posaconazole
💬 | - | - | 3件: 60 60, 65, 299 💬 |
394 | Noxafil 40 mg/ml oral solution | 1件: Posaconazole Posaconazole | 1件: Posaconazole
Posaconazole
💬 | - | - | 1件: 65 65 💬 |
395 | NutropinAq 10mg/2ml (30 I.E.) Injektionsllösung | 1件: Somatotropin Somatotropin | - | - | - | 1件: 65 65 💬 |
396 | OCTA-C1-INH | 1件: Human C1-esterase inhibitor Human C1-esterase inhibitor | - | - | - | 1件: 65 65 💬 |
397 | Octagam | - | - | - | - | 2件: 13 13, 65 💬 |
398 | Octagam 10% | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 3件: 50 50, 63, 65 💬 |
399 | Octagam 5% | - | - | - | - | 2件: 13 13, 65 💬 |
400 | OCTAGAM 50 mg/ml oldatos infúzió | - | - | - | - | 1件: 65 65 💬 |
401 | Octanorm | - | - | - | - | 2件: 50 50, 65 💬 |
402 | Octanorm 16.5% | - | - | - | - | 2件: 50 50, 65 💬 |
403 | OMALIZUMAB | 1件: Omalizumab Omalizumab | 1件: Omalizumab
Omalizumab
💬 | 1件: FCER1A FCER1A 💬 | 4件: Asthma Asthma, Fc epsilon RI signaling pathway, Phospholipase D signaling pathway, Sphingolipid signaling pathway 💬 | 7件: 46 46, 53, 65, 98, 162, 226, 299 💬 |
404 | Omalizumab (Xolair) | 1件: Omalizumab Omalizumab | 1件: Omalizumab
Omalizumab
💬 | 1件: FCER1A FCER1A 💬 | 4件: Asthma Asthma, Fc epsilon RI signaling pathway, Phospholipase D signaling pathway, Sphingolipid signaling pathway 💬 | 1件: 65 65 💬 |
405 | OpenBiome FMT product FMP250 | - | - | - | - | 1件: 65 65 💬 |
406 | ORENCIA | 1件: Abatacept Abatacept | 1件: Abatacept
Abatacept
💬 | 2件: CD80 CD80, CD86 💬 | 13件: Allograft rejection Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Virion - Adenovirus 💬 | 14件: 44 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 160, 222, 271 💬 |
407 | ORENCIA® 125 mg solution for injection in pre-filled syringe | 1件: Abatacept Abatacept | 1件: Abatacept
Abatacept
💬 | 2件: CD80 CD80, CD86 💬 | 13件: Allograft rejection Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Virion - Adenovirus 💬 | 1件: 65 65 💬 |
408 | Other hematological Agents | - | - | - | - | 1件: 65 65 💬 |
409 | OTL-101 | - | - | - | - | 1件: 65 65 💬 |
410 | OTL-103 | - | - | - | - | 1件: 65 65 💬 |
411 | OTL-103 Dispersion for Infusion | - | - | - | - | 1件: 65 65 💬 |
412 | OVASTAT | 1件: Treosulfan Treosulfan | 1件: Treosulfan
Treosulfan
💬 | - | - | 2件: 13 13, 65 💬 |
413 | Ovastat 1000 | 1件: Treosulfan Treosulfan | 1件: Treosulfan
Treosulfan
💬 | - | - | 2件: 13 13, 65 💬 |
414 | Ovastat 1000 (Treosulfan injection) | 1件: Treosulfan Treosulfan | 1件: Treosulfan
Treosulfan
💬 | - | - | 1件: 65 65 💬 |
415 | Ovastat 1000 mg, powder for solution for infusion | 1件: Treosulfan Treosulfan | 1件: Treosulfan
Treosulfan
💬 | - | - | 1件: 65 65 💬 |
416 | Ovastat 5000 | 1件: Treosulfan Treosulfan | 1件: Treosulfan
Treosulfan
💬 | - | - | 2件: 13 13, 65 💬 |
417 | Ovastat 5000 (Treosulfan injection) | 1件: Treosulfan Treosulfan | 1件: Treosulfan
Treosulfan
💬 | - | - | 1件: 65 65 💬 |
418 | Ovastat 5000 mg, powder for solution for infusion | 1件: Treosulfan Treosulfan | 1件: Treosulfan
Treosulfan
💬 | - | - | 1件: 65 65 💬 |
419 | Palifermin | 1件: Palifermin Palifermin | 1件: Palifermin
Palifermin
💬 | 1件: FGFR2 FGFR2 💬 | 13件: Calcium signaling pathway Calcium signaling pathway, Central carbon metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Gastric cancer, MAPK signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Signaling pathways regulating pluripotency of stem cells 💬 | 5件: 13 13, 36, 38, 39, 65 💬 |
420 | Pantoprazole | 1件: Pantoprazole Pantoprazole | 1件: Pantoprazole
Pantoprazole
💬 | 2件: ATP4A ATP4A, ATP4B 💬 | 4件: Collecting duct acid secretion Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬 | 2件: 13 13, 65 💬 |
421 | Pantoprazolo 20 mg gastro-resistant tablets | - | - | - | - | 1件: 65 65 💬 |
422 | PCCLchimGp91s lentiviral vector transduced CD34+ cells infusion | - | - | - | - | 1件: 65 65 💬 |
423 | PEG | - | - | - | - | 15件: 6 6, 13, 41, 46, 60, 65, 78, 96, 97, 140, 144, 240, 246, 299, 337 💬 |
424 | Peg-Ada | - | - | - | - | 1件: 65 65 💬 |
425 | PEG-interleukin-2 | 1件: Human interleukin-2 Human interleukin-2 | - | - | - | 1件: 65 65 💬 |
426 | Pentamidine | 1件: Pentamidine Pentamidine | 1件: Pentamidine
Pentamidine
💬 | - | - | 2件: 61 61, 65 💬 |
427 | Peripheral Blood Stem Cells | - | - | - | - | 2件: 51 51, 65 💬 |
428 | PHA-022121 | - | - | - | - | 1件: 65 65 💬 |
429 | PHA-022121 high dose | - | - | - | - | 1件: 65 65 💬 |
430 | PHA-022121 low dose | - | - | - | - | 1件: 65 65 💬 |
431 | PHA-022121 medium dose | - | - | - | - | 1件: 65 65 💬 |
432 | PHA-022121 selected dose | - | - | - | - | 1件: 65 65 💬 |
433 | Phagocyte Oxidase Subunit Transduced CD34 Hematopoietic Stem Cells | - | - | - | - | 1件: 65 65 💬 |
434 | Pheripheral blood stem cells | - | - | - | - | 1件: 65 65 💬 |
435 | Phosphate | 1件: Phosphate ion Phosphate ion | - | - | - | 32件: 2 2, 3, 6, 11, 12, 13, 28, 36, 46, 49, 51, 53, 60, 62, 65, 70, 78, 81, 83, 90, 96, 97, 164, 235, 238, 256, 276, 283, 284, 285, 286, 299 💬 |
436 | PHVS416 | - | - | - | - | 1件: 65 65 💬 |
437 | PID | - | - | - | - | 1件: 65 65 💬 |
438 | Pioglitazone | 1件: Pioglitazone Pioglitazone | 1件: Pioglitazone
Pioglitazone
💬 | 1件: PPARG PPARG 💬 | 11件: AMPK signaling pathway AMPK signaling pathway, Huntington disease, Lipid and atherosclerosis, Longevity regulating pathway, Non-alcoholic fatty liver disease, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer 💬 | 17件: 2 2, 6, 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299 💬 |
439 | PLERIXAFOR | 1件: Plerixafor Plerixafor | 1件: Plerixafor
Plerixafor
💬 | 1件: CXCR4 CXCR4 💬 | 14件: Axon guidance Axon guidance, Calcium signaling pathway, Chemokine signaling pathway, Cytokine-cytokine receptor interaction, Endocytosis, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Intestinal immune network for IgA production, Leukocyte transendothelial migration, Pathways in cancer, Regulation of actin cytoskeleton, Viral life cycle - HIV-1, Viral protein interaction with cytokine and cytokine receptor, Virion - Human immunodeficiency virus 💬 | 4件: 20 20, 65, 285, 299 💬 |
440 | Plerixafor for Conditioning before HSCT. | 1件: Plerixafor Plerixafor | 1件: Plerixafor
Plerixafor
💬 | 1件: CXCR4 CXCR4 💬 | 14件: Axon guidance Axon guidance, Calcium signaling pathway, Chemokine signaling pathway, Cytokine-cytokine receptor interaction, Endocytosis, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Intestinal immune network for IgA production, Leukocyte transendothelial migration, Pathways in cancer, Regulation of actin cytoskeleton, Viral life cycle - HIV-1, Viral protein interaction with cytokine and cytokine receptor, Virion - Human immunodeficiency virus 💬 | 1件: 65 65 💬 |
441 | PnCJ PPS | - | - | - | - | 1件: 65 65 💬 |
442 | PNEUMO 23 | - | - | - | - | 1件: 65 65 💬 |
443 | Pneumovax® (pneumococcal polysaccharide vaccine) | - | - | - | - | 1件: 65 65 💬 |
444 | Polyclonal IgG | - | - | - | - | 1件: 65 65 💬 |
445 | Polymerase chain reaction | - | - | - | - | 2件: 65 65, 285 💬 |
446 | Posaconazole | 1件: Posaconazole Posaconazole | 1件: Posaconazole
Posaconazole
💬 | - | - | 3件: 60 60, 65, 299 💬 |
447 | Posaconazole (PSZ) | 1件: Posaconazole Posaconazole | 1件: Posaconazole
Posaconazole
💬 | - | - | 1件: 65 65 💬 |
448 | PPS | - | - | - | - | 1件: 65 65 💬 |
449 | PREDNISOLONE | 1件: Prednisolone Prednisolone | 1件: Prednisolone
Prednisolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 42件: 3 3, 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300 💬 |
450 | Prednisone | 1件: Prednisone Prednisone | 1件: Prednisone
Prednisone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 45件: 2 2, 11, 13, 14, 19, 26, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 61, 63, 64, 65, 66, 79, 81, 84, 85, 86, 95, 96, 97, 113, 162, 164, 205, 222, 224, 228, 283, 284, 288, 299, 300, 307, 331 💬 |
451 | PREVENAR | - | - | - | - | 1件: 65 65 💬 |
452 | Prevenar® (7-valent pneumococcal conjugate vaccine) | - | - | - | - | 1件: 65 65 💬 |
453 | PRIVIGEN | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 4件: 11 11, 14, 51, 65 💬 |
454 | Privigen® | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 3件: 14 14, 63, 65 💬 |
455 | Procarbazine | 1件: Procarbazine Procarbazine | 1件: Procarbazine
Procarbazine
💬 | - | - | 1件: 65 65 💬 |
456 | Progynova 21 mite | - | - | - | - | 1件: 65 65 💬 |
457 | Proleukin | 1件: Aldesleukin Aldesleukin | 1件: Aldesleukin
Aldesleukin
💬 | 3件: IL2RA IL2RA, IL2RB, IL2RG 💬 | 14件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Inflammatory bowel disease, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Primary immunodeficiency, Th1 and Th2 cell differentiation, Th17 cell differentiation, Transcriptional misregulation in cancer, Viral protein interaction with cytokine and cytokine receptor 💬 | 3件: 2 2, 49, 65 💬 |
458 | PROLEUKIN® S | 1件: Aldesleukin Aldesleukin | 1件: Aldesleukin
Aldesleukin
💬 | 3件: IL2RA IL2RA, IL2RB, IL2RG 💬 | 14件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Inflammatory bowel disease, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Primary immunodeficiency, Th1 and Th2 cell differentiation, Th17 cell differentiation, Transcriptional misregulation in cancer, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 65 65 💬 |
459 | Promacta | 1件: Eltrombopag Eltrombopag | - | - | - | 2件: 63 63, 65 💬 |
460 | Prometic's Immune Globulin Intravenous 10% | - | - | - | - | 1件: 65 65 💬 |
461 | PSRS11.EFS.IL2RG.pre* retroviral vector | - | - | - | - | 1件: 65 65 💬 |
462 | PSRS11.EFS.IL2RG.pre* retroviral vector transduce | - | - | - | - | 1件: 65 65 💬 |
463 | PSRS11.EFS.IL2RG.pre* retroviral vector transduced cells | - | - | - | - | 1件: 65 65 💬 |
464 | PTH | - | - | - | - | 2件: 65 65, 235 💬 |
465 | PTH 1-34 | 1件: Teriparatide Teriparatide | 1件: Teriparatide
Teriparatide
💬 | 1件: PTH1R PTH1R 💬 | 3件: Endocrine and other factor-regulated calcium reabsorption Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action 💬 | 2件: 65 65, 235 💬 |
466 | Purified Vero Cell Vaccine) | - | - | - | - | 1件: 65 65 💬 |
467 | PYRIMETHAMINE | 1件: Pyrimethamine Pyrimethamine | 1件: Pyrimethamine
Pyrimethamine
💬 | - | - | 4件: 2 2, 4, 19, 65 💬 |
468 | R-hIL-18BP | - | - | - | - | 1件: 65 65 💬 |
469 | Rabbit | 1件: Rabbit Rabbit | - | - | - | 8件: 11 11, 13, 49, 51, 60, 65, 96, 285 💬 |
470 | Rabbit anti-thymocyte globulin | 1件: Rabbit Rabbit | - | - | - | 1件: 65 65 💬 |
471 | RAG1 LV CD34+ cells | - | - | - | - | 1件: 65 65 💬 |
472 | Ranitidine | 1件: Ranitidine Ranitidine | 1件: Ranitidine
Ranitidine
💬 | 1件: HRH2 HRH2 💬 | 3件: Calcium signaling pathway Calcium signaling pathway, Gastric acid secretion, Neuroactive ligand-receptor interaction 💬 | 2件: 13 13, 65 💬 |
473 | Recombinant human hyaluronidase | 2件: Hyaluronidase Hyaluronidase, Hyaluronidase (human recombinant) | 3件: Hyaluronidase
Hyaluronidase
,
Hyaluronidase
,
Hyaluronidase
💬 | - | - | 3件: 14 14, 28, 65 💬 |
474 | Recombinant Human Hyaluronidase (rHuPH20) | 2件: Hyaluronidase Hyaluronidase, Hyaluronidase (human recombinant) | 3件: Hyaluronidase
Hyaluronidase
,
Hyaluronidase
,
Hyaluronidase
💬 | - | - | 1件: 65 65 💬 |
475 | Recombinant human hyaluronidase (rHuPH20)+ immune globulin intravenous (IGIV) | 2件: Hyaluronidase Hyaluronidase, Hyaluronidase (human recombinant) | 3件: Hyaluronidase
Hyaluronidase
,
Hyaluronidase
,
Hyaluronidase
💬 | - | - | 1件: 65 65 💬 |
476 | Recombinant human hyaluronidase + immune globulin intravenous | 2件: Hyaluronidase Hyaluronidase, Hyaluronidase (human recombinant) | 3件: Hyaluronidase
Hyaluronidase
,
Hyaluronidase
,
Hyaluronidase
💬 | - | - | 1件: 65 65 💬 |
477 | Reduced Intensity Conditioning | - | - | - | - | 2件: 19 19, 65 💬 |
478 | Reduced Intensity Preparative Regimen | - | - | - | - | 3件: 62 62, 65, 284 💬 |
479 | Reduced Toxicity Ablative Regimen | - | - | - | - | 3件: 62 62, 65, 284 💬 |
480 | Release | 1件: Manganese citrate Manganese citrate | - | - | - | 12件: 6 6, 8, 13, 46, 65, 78, 81, 96, 97, 206, 226, 299 💬 |
481 | Retroviral SF71-gp91phox transduced CD34+ cells | - | - | - | - | 1件: 65 65 💬 |
482 | RhuCD40L | - | - | - | - | 1件: 65 65 💬 |
483 | RI-002 | - | - | - | - | 1件: 65 65 💬 |
484 | Rifaximin | 1件: Rifaximin Rifaximin | 1件: Rifaximin
Rifaximin
💬 | - | - | 8件: 6 6, 65, 93, 96, 97, 99, 296, 299 💬 |
485 | Rimiducid | 1件: Rimiducid Rimiducid | 1件: Rimiducid
Rimiducid
💬 | 1件: CASP9 CASP9 💬 | 35件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Apoptosis, Apoptosis - multiple species, Colorectal cancer, Endometrial cancer, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Huntington disease, Influenza A, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Lipid and atherosclerosis, Measles, Non-small cell lung cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Parkinson disease, Pathogenic Escherichia coli infection, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platinum drug resistance, Prion disease, Prostate cancer, Small cell lung cancer, Thyroid hormone signaling pathway, Toxoplasmosis, Tuberculosis, VEGF signaling pathway, Viral myocarditis, p53 signaling pathway 💬 | 6件: 19 19, 60, 65, 284, 285, 326 💬 |
486 | RITUXIMAB | 1件: Rituximab Rituximab | 1件: Rituximab
Rituximab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 48件: 11 11, 13, 14, 19, 26, 35, 36, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 53, 55, 56, 60, 61, 63, 64, 65, 66, 83, 84, 85, 86, 93, 94, 96, 97, 162, 222, 229, 256, 271, 274, 283, 284, 285, 288, 296, 300, 331 💬 |
487 | Rituximab (RTX) and Azathioprine (AZA) | 2件: Azathioprine Azathioprine, Rituximab | 2件: Azathioprine
Azathioprine
,
Rituximab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 65 65 💬 |
488 | Romiplostim | 1件: Romiplostim Romiplostim | 1件: Romiplostim
Romiplostim
💬 | 1件: MPL MPL 💬 | 2件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway 💬 | 4件: 60 60, 63, 64, 65 💬 |
489 | RP-L201 | - | - | - | - | 1件: 65 65 💬 |
490 | RTX | - | - | - | - | 5件: 11 11, 46, 65, 222, 240 💬 |
491 | Ruxolitinib | 1件: Ruxolitinib Ruxolitinib | 1件: Ruxolitinib
Ruxolitinib
💬 | 2件: JAK1 JAK1, JAK2 💬 | 35件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 3件: 60 60, 65, 228 💬 |
492 | SC treatment with IGSC, 10% with rHuPH20 followed by IV/IGSC, 10% only (safety) | - | - | - | - | 1件: 65 65 💬 |
493 | SC treatment with IGSC, 10% with rHuPH20 followed by SC/IGSC, 10% only (safety) | - | - | - | - | 1件: 65 65 💬 |
494 | SCID screening | - | - | - | - | 1件: 65 65 💬 |
495 | SCYX-7158 | - | - | - | - | 1件: 65 65 💬 |
496 | Sebetralstat | - | - | - | - | 1件: 65 65 💬 |
497 | Single infusion of autologous CD34+ cells transduced with the self-inactivating (SIN) gammaretroviral vector pSRS11.EFS.IL2RG.pre | - | - | - | - | 1件: 65 65 💬 |
498 | Sirolimus | 1件: Sirolimus Sirolimus | 1件: Sirolimus
Sirolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 35件: 13 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 98, 137, 157, 158, 192, 222, 277, 278, 279, 280, 281, 283, 300, 331 💬 |
499 | Somatic gene-therapy by X-CGD | - | - | - | - | 1件: 65 65 💬 |
500 | Somatotropin | 1件: Somatotropin Somatotropin | - | - | - | 4件: 3 3, 65, 78, 236 💬 |
501 | Somatropin | 1件: Somatotropin Somatotropin | - | - | - | 19件: 2 2, 3, 19, 46, 65, 74, 75, 78, 96, 107, 113, 187, 193, 195, 238, 265, 274, 276, 299 💬 |
502 | Somatropin, Clonidine, L-Arginin-Hydrochloride, Estradiol valerate | 5件: Arginine Arginine, Clonidine, Estradiol, Estradiol valerate, Somatotropin | 4件: Estradiol
Estradiol
,
Clonidine
,
Estradiol valerate
,
Arginine
💬 | 5件: ADRA2A ADRA2A, ADRA2B, ADRA2C, ESR1, ESR2 💬 | 12件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Neuroactive ligand-receptor interaction, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 65 65 💬 |
503 | STA-5326 | - | - | - | - | 2件: 65 65, 96 💬 |
504 | Stelara (ustekinumab) | 1件: Ustekinumab Ustekinumab | 1件: Ustekinumab
Ustekinumab
💬 | 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 65 65 💬 |
505 | Stem Cell Transplant | - | - | - | - | 2件: 60 60, 65 💬 |
506 | Stem Cell Transplantation | - | - | - | - | 10件: 13 13, 19, 20, 46, 65, 90, 125, 164, 234, 326 💬 |
507 | STRIMVELIS | - | - | - | - | 1件: 65 65 💬 |
508 | Subcuvia | - | - | - | - | 3件: 14 14, 49, 65 💬 |
509 | Subgam | - | - | - | - | 1件: 65 65 💬 |
510 | Sulfadoxine | 1件: Sulfadoxine Sulfadoxine | 1件: Sulfadoxine
Sulfadoxine
💬 | - | - | 1件: 65 65 💬 |
511 | Suspension of autologous CD34+cells transduced with the G1XCGD viral vector | - | - | - | - | 1件: 65 65 💬 |
512 | T-Cell Depleted & CD34+Select/w/StemCell Enriched Product | - | - | - | - | 1件: 65 65 💬 |
513 | Tabelecleucel | 1件: Tabelecleucel Tabelecleucel | 1件: Tabelecleucel
Tabelecleucel
💬 | - | - | 1件: 65 65 💬 |
514 | Tablets Fexinidazole | 1件: Fexinidazole Fexinidazole | 1件: Fexinidazole
Fexinidazole
💬 | - | - | 1件: 65 65 💬 |
515 | Tacrolimus | 1件: Tacrolimus Tacrolimus | 2件: Tacrolimus
Tacrolimus
,
Tacrolimus
💬 | 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 34件: 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬 |
516 | Tacrolimus (Tacro) | 1件: Tacrolimus Tacrolimus | 2件: Tacrolimus
Tacrolimus
,
Tacrolimus
💬 | 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 65 65 💬 |
517 | TADEKINIG ALFA | 1件: Tadekinig alfa Tadekinig alfa | - | - | - | 1件: 65 65 💬 |
518 | TAK-771 | - | - | - | - | 2件: 14 14, 65 💬 |
519 | Target Sequencing by NGS ( Next-generation sequencing) | - | - | - | - | 1件: 65 65 💬 |
520 | TBX-1400 | - | - | - | - | 1件: 65 65 💬 |
521 | Thalidomide | 1件: Thalidomide Thalidomide | 1件: Thalidomide
Thalidomide
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 20件: 2 2, 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬 |
522 | Therapeutic Allogeneic Lymphocytes | - | - | - | - | 3件: 60 60, 65, 285 💬 |
523 | There is no recommended INN | - | - | - | - | 1件: 65 65 💬 |
524 | Thiotepa | 1件: Thiotepa Thiotepa | 1件: Thiotepa
Thiotepa
💬 | - | - | 12件: 13 13, 19, 20, 28, 51, 60, 65, 85, 96, 164, 284, 285 💬 |
525 | Thiotepa--escalated dose | 1件: Thiotepa Thiotepa | 1件: Thiotepa
Thiotepa
💬 | - | - | 4件: 19 19, 20, 65, 284 💬 |
526 | Thiotepa--single daily dose | 1件: Thiotepa Thiotepa | 1件: Thiotepa
Thiotepa
💬 | - | - | 4件: 19 19, 20, 65, 284 💬 |
527 | Thymafalsin | - | - | - | - | 1件: 65 65 💬 |
528 | THYMALFASIN | 1件: Thymalfasin Thymalfasin | 1件: Thymalfasin
Thymalfasin
💬 | - | - | 1件: 65 65 💬 |
529 | Thymoglobulin | 1件: Antithymocyte immunoglobulin (rabbit) Antithymocyte immunoglobulin (rabbit) | - | - | - | 7件: 36 36, 51, 60, 65, 96, 285, 326 💬 |
530 | Thymus Tissue for Transplantation | - | - | - | - | 1件: 65 65 💬 |
531 | Thymus/Parathyroid Transplantation | - | - | - | - | 2件: 65 65, 235 💬 |
532 | To be confirmed | - | - | - | - | 3件: 46 46, 65, 97 💬 |
533 | Tociluzumab | - | - | - | - | 1件: 65 65 💬 |
534 | Tofacitinib | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 15件: 11 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬 |
535 | Total Body Irradiation | - | - | - | - | 1件: 65 65 💬 |
536 | Traditional treatment of CGD and TB | - | - | - | - | 1件: 65 65 💬 |
537 | Transduced Lymphocytes | - | - | - | - | 1件: 65 65 💬 |
538 | Transduced patient CD34+ cells | - | - | - | - | 1件: 65 65 💬 |
539 | Transplant Conditioning with Mobilization and Alemtuzumab | 1件: Alemtuzumab Alemtuzumab | 1件: Alemtuzumab
Alemtuzumab
💬 | 1件: CD52 CD52 💬 | - | 1件: 65 65 💬 |
540 | Transplant Conditioning with Mobilization Only | - | - | - | - | 1件: 65 65 💬 |
541 | Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan | 4件: Alemtuzumab Alemtuzumab, Fludarabine, Melphalan, Thiotepa | 4件: Melphalan
Melphalan
,
Thiotepa
,
Alemtuzumab
,
Fludarabine
💬 | 2件: CD52 CD52, RRM1 💬 | 6件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Nucleotide metabolism, Purine metabolism, Pyrimidine metabolism 💬 | 2件: 65 65, 164 💬 |
542 | TREOSULFAN | 1件: Treosulfan Treosulfan | 1件: Treosulfan
Treosulfan
💬 | - | - | 6件: 13 13, 19, 62, 65, 283, 286 💬 |
543 | Triheptanoin | 1件: Triheptanoin Triheptanoin | 1件: Triheptanoin
Triheptanoin
💬 | - | - | 10件: 2 2, 8, 65, 149, 156, 248, 256, 257, 317, 324 💬 |
544 | TYF-ADA gene-modified autologous stem cells | - | - | - | - | 1件: 65 65 💬 |
545 | TYF-IL-2Rg gene-modified autologous stem cells | - | - | - | - | 1件: 65 65 💬 |
546 | Unrelated BM with T cell depletion | - | - | - | - | 1件: 65 65 💬 |
547 | Unrelated cord blood | - | - | - | - | 1件: 65 65 💬 |
548 | Ustekinumab | 1件: Ustekinumab Ustekinumab | 1件: Ustekinumab
Ustekinumab
💬 | 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 16件: 37 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬 |
549 | Valacyclovir | 1件: Valaciclovir Valaciclovir | 2件: Valaciclovir
Valaciclovir
,
Valaciclovir hydrochloride hydrate
💬 | - | - | 1件: 65 65 💬 |
550 | Valproic Acid | 1件: Valproic acid Valproic acid | 1件: Valproic acid
Valproic acid
💬 | 7件: ABAT ABAT, ALDH5A1, CACNA1G, CACNA1H, CACNA1I, GAD1, GAD2 💬 | 17件: Alanine, aspartate and glutamate metabolism Alanine, aspartate and glutamate metabolism, Aldosterone synthesis and secretion, Butanoate metabolism, Calcium signaling pathway, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, GABAergic synapse, GnRH secretion, MAPK signaling pathway, Metabolic pathways, Propanoate metabolism, Taurine and hypotaurine metabolism, Type I diabetes mellitus, Type II diabetes mellitus, Valine, leucine and isoleucine degradation, beta-Alanine metabolism 💬 | 7件: 3 3, 5, 26, 65, 90, 222, 256 💬 |
551 | Verorab® (PVRV | - | - | - | - | 1件: 65 65 💬 |
552 | Vigantol | - | - | - | - | 4件: 13 13, 65, 96, 97 💬 |
553 | Vinblastine | 1件: Vinblastine Vinblastine | 1件: Vinblastine
Vinblastine
💬 | 9件: TUBB TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 | 10件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Gap junction, Huntington disease, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬 | 2件: 34 34, 65 💬 |
554 | Vinblastine, vincristine, prednisone, daunorubicin | 4件: Daunorubicin Daunorubicin, Prednisone, Vinblastine, Vincristine | 4件: Prednisone
Prednisone
,
Daunorubicin
,
Vinblastine
,
Vincristine
💬 | 12件: NR3C1 NR3C1, TOP2A, TOP2B, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 | 12件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Gap junction, Huntington disease, Neuroactive ligand-receptor interaction, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Platinum drug resistance, Prion disease, Salmonella infection 💬 | 1件: 65 65 💬 |
555 | Vincristine | 1件: Vincristine Vincristine | 1件: Vincristine
Vincristine
💬 | 9件: TUBB TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 | 10件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Gap junction, Huntington disease, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬 | 4件: 26 26, 34, 65, 331 💬 |
556 | Vitamin D3 | 1件: Cholecalciferol Cholecalciferol | 1件: Cholecalciferol
Cholecalciferol
💬 | 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 12件: 6 6, 13, 20, 46, 49, 51, 53, 60, 65, 96, 97, 299 💬 |
557 | Vivaglobin | - | - | - | - | 2件: 14 14, 65 💬 |
558 | VM106 | - | - | - | - | 1件: 65 65 💬 |
559 | Water | 1件: Water Water | 1件: Water
Water
💬 | - | - | 21件: 2 2, 5, 6, 13, 17, 22, 35, 46, 53, 57, 63, 65, 67, 78, 84, 96, 97, 206, 226, 278, 299 💬 |
560 | Whole Exome Sequencing | - | - | - | - | 3件: 65 65, 120, 149 💬 |
561 | X vivo gene therapy | - | - | - | - | 1件: 65 65 💬 |
562 | X4P-001 | - | - | - | - | 1件: 65 65 💬 |
563 | XELJANZ (tofacitinib) | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 65 65 💬 |
564 | Xifaxan | 1件: Rifaximin Rifaximin | 1件: Rifaximin
Rifaximin
💬 | - | - | 2件: 65 65, 94 💬 |
565 | Zadaxin | - | - | - | - | 2件: 65 65, 299 💬 |
566 | ZARZIO | 1件: Filgrastim Filgrastim | 1件: Filgrastim
Filgrastim
💬 | 1件: CSF3R CSF3R 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer 💬 | 3件: 38 38, 65, 285 💬 |
567 | Zoledronate | 1件: Zoledronic acid Zoledronic acid | 2件: Zoledronic acid
Zoledronic acid
,
Zoledronic acid
💬 | 1件: FDPS FDPS 💬 | 4件: Human T-cell leukemia virus 1 infection Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 2件: 46 46, 65 💬 |